Norwalk virus: How infectious is it
Noroviruses are major agents of viral gastroenteritis worldwide. The infectivity of Norwalk virus, the prototype norovirus, has been studied in susceptible human volunteers. A new variant of the hit theory model of microbial infection was developed to estimate the variation in Norwalk virus infectiv...
Saved in:
Published in | Journal of medical virology Vol. 80; no. 8; pp. 1468 - 1476 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.08.2008
Wiley-Liss |
Subjects | |
Online Access | Get full text |
ISSN | 0146-6615 1096-9071 1096-9071 |
DOI | 10.1002/jmv.21237 |
Cover
Summary: | Noroviruses are major agents of viral gastroenteritis worldwide. The infectivity of Norwalk virus, the prototype norovirus, has been studied in susceptible human volunteers. A new variant of the hit theory model of microbial infection was developed to estimate the variation in Norwalk virus infectivity, as well as the degree of virus aggregation, consistent with independent (electron microscopic) observations. Explicit modeling of viral aggregation allows us to express virus infectivity per single infectious unit (particle). Comparison of a primary and a secondary inoculum showed that passage through a human host does not change Norwalk virus infectivity. We estimate the average probability of infection for a single Norwalk virus particle to be close to 0.5, exceeding that reported for any other virus studied to date. Infected subjects had a dose-dependent probability of becoming ill, ranging from 0.1 (at a dose of 10³ NV genomes) to 0.7 (at 10⁸ virus genomes). A norovirus dose response model is important for understanding its transmission and essential for development of a quantitative risk model. Norwalk virus is a valuable model system to study virulence because genetic factors are known for both complete and partial protection; the latter can be quantitatively described as heterogeneity in dose response models. J. Med. Virol. 80:1468-1476, 2008. |
---|---|
Bibliography: | http://dx.doi.org/10.1002/jmv.21237 The views represented in this paper are solely those of the authors and not the representative institution. Use of tradenames and products is not an endorsement. USEPA STAR - No. R-826139 PHS - No. RR00046 ark:/67375/WNG-WFCL9F7G-4 U.S. Environmental protection Agency (cooperative agreement) - No. R-82936501 European Commission (Sixth Framework Programme) - No. SSP22-CT-2004-502084 National Institutes of Health istex:62967203DE71E149D2A1062DBBEE84441C6EB645 ArticleID:JMV21237 NIAID - No. 5R01 A105U351-03 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0146-6615 1096-9071 1096-9071 |
DOI: | 10.1002/jmv.21237 |